Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Fourpath Capital Management LLC

Fourpath Capital Management LLC increased its stake in Novo Nordisk A/S (NYSE:NVO) by 10.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,652 shares of the company’s stock after purchasing an additional 346 shares during the quarter. Fourpath Capital Management LLC’s holdings in Novo Nordisk A/S were worth $254,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Farther Finance Advisors LLC lifted its holdings in Novo Nordisk A/S by 37.9% in the 1st quarter. Farther Finance Advisors LLC now owns 69,344 shares of the company’s stock valued at $4,717,000 after acquiring an additional 19,061 shares during the last quarter. Range Financial Group LLC raised its holdings in Novo Nordisk A/S by 11.8% during the 1st quarter. Range Financial Group LLC now owns 11,141 shares of the company’s stock worth $774,000 after buying an additional 1,177 shares during the period. Baldwin Wealth Partners LLC MA raised its holdings in Novo Nordisk A/S by 248.0% during the 1st quarter. Baldwin Wealth Partners LLC MA now owns 169,516 shares of the company’s stock worth $11,771,000 after buying an additional 120,808 shares during the period. Wesbanco Bank Inc. raised its holdings in Novo Nordisk A/S by 72.4% during the 1st quarter. Wesbanco Bank Inc. now owns 177,801 shares of the company’s stock worth $12,347,000 after buying an additional 74,685 shares during the period. Finally, First Citizens Bank & Trust Co. raised its holdings in Novo Nordisk A/S by 1.5% during the 1st quarter. First Citizens Bank & Trust Co. now owns 18,597 shares of the company’s stock worth $1,291,000 after buying an additional 270 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the topic of several recent analyst reports. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Guggenheim downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. BMO Capital Markets reiterated a “market perform” rating and issued a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Friday, June 6th. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $112.00.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $79.39 on Wednesday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The stock has a market cap of $356.28 billion, a P/E ratio of 24.13, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The stock’s 50-day moving average price is $66.26 and its two-hundred day moving average price is $80.17.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion for the quarter. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.